Core Viewpoint - The stock of He Yu-B (02256) has seen a significant increase, rising over 7% during trading, with a current price of 15.03 HKD and a trading volume of 9.1686 million HKD, following the announcement of positive clinical trial results for its drug pimicotinib [1] Group 1: Company Developments - He Yu-B's subsidiary, Shanghai He Yu Biomedical Technology Co., Ltd., presented long-term efficacy and safety data from the global Phase III MANEUVER study of pimicotinib for treating tenosynovial giant cell tumor (TGCT) patients at the 2025 European Society for Medical Oncology (ESMO) conference [1] - Pimicotinib has been prioritized for review by the National Medical Products Administration (NMPA) in China for adult TGCT patients requiring systemic treatment and has received Breakthrough Therapy Designation (BTD) from the NMPA [1] - The drug has also been granted BTD by the U.S. Food and Drug Administration (FDA) and received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for overseas markets [1]
港股异动 | 和誉-B(02256)盘中涨超7% 于2025年ESMO会议展示匹米替尼临床III期相关研究数据